UP!

MELA $1.12

MELA target price
1.12
0
0
MELA Sciences, Inc.
Type
Public
Traded as NASDAQ: MELA
Headquarters Irvington, New York, United States
Website melasciences.com

MELA Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company’s flagship product, MelaFind®, is intended to be used when a trained dermatologist chooses to obtain additional information to help decide whether to biopsy certain clinically atypical pigmented skin lesions. The FDA has approved MELA Sciences’ MelaFind® pre-market approval application for use in the United States. Following completion of a successful conformity assessment procedure, MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County.

If caught early, melanoma can be cured.

Melanoma is the deadliest form of skin cancer, responsible for about 75% of skin cancer fatalities, according to the Skin Cancer Foundation.

There are an estimated 135,000 new cases of melanoma diagnosed in the U.S. every year.

Every hour, one person in the U.S. dies of melanoma and 15 people are diagnosed with the disease, according to the American Cancer Society.

What causes melanoma?

Melanoma is frequently caused by exposure to the sun, which triggers the uncontrolled growth of skin pigment cells or melanocytes. On the surface of the skin, melanoma can look like other irregular, harmless moles. However, beneath the surface there may be a peculiar cellular growth pattern.

Anyone can get melanoma, though it is more prevalent in certain parts of the country and among Caucasians. Dermatologists are especially concerned because melanoma is the most common cancer in people aged 25–29 and the second most common cancer in teens and young adults aged 15–29.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2015-08-24 Boost Price Target HC Wainwright Buy $4.50 to $5.00
2015-06-25 Reiterated Rating HC Wainwright Buy
2015-03-12 Reiterated Rating HC Wainwright Buy
2014-08-18 Initiated H.C. Wainwright Buy $4.50
2014-08-18 Initiated Coverage HC Wainwright Buy $4.50
2012-09-24 Upgrade WBB Securities Hold to Speculative Buy $2 to $4
2011-11-02 Reiterated Needham Buy $14 to $20
2010-11-17 Upgrade WBB Securities Sell Short to Hold $5 to $2
2010-09-10 Initiated BioLogic Equity Research Sell
2010-05-11 Downgrade Brean Murray Buy to Hold
2010-03-31 Initiated Brean Murray Buy $9
2010-03-25 Downgrade WBB Securities Sell to Sell Short $7.25 to $5
2010-03-25 Downgrade Roth Capital Hold to Sell $12 to $4
2009-11-30 Initiated WBB Securities Sell $7.25
2009-11-12 Initiated Boenning & Scattergood Outperform $12.50
2009-08-18 Initiated Oppenheimer Outperform $11
2009-02-13 Initiated Caris & Company Buy $9
2008-05-13 Reiterated Jesup & Lamont Buy $8 to $9.50
2015-08-24 Boost Price Target HC Wainwright Buy $4.50 to $5.00
2015-06-25 Reiterated Rating HC Wainwright Buy
2015-03-12 Reiterated Rating HC Wainwright Buy
2014-08-18 Initiated H.C. Wainwright Buy $4.50
2014-08-18 Initiated Coverage HC Wainwright Buy $4.50

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In MELA 4 funds of 2213 total. Show all

Fund name Ticker shares
BlackRock Institutional Trust Company, N.A. 0.32M
BlackRock Fund Advisors 4790
Carnick & Kubik, LLC 600
MetLife Securities, Inc 204

Major Shareholders

Name Relationship Total Shares Holding stocks
Broadfin Healthcare Master Fund Ltd 19.34%  (1008297) AEGR / FLML / MELA / MRTX / PETX / PGNX / QLTI / REPH /
Lufkin Dan W 8.96%  (467115) MELA /
Gulfo Joseph V CEO & President 3.99%  (208311) MELA /
Coradini Robert 2.67%  (139024) MELA /
Castleman Breaux 2.25%  (117238) ISIS / MELA / USMD /
DIMUN ANTHONY J 1.94%  (101013) MELA /
STEWART MICHAEL R 1.92%  (100000) MELA / PHMD /
Crane Rosemary A CEO and President 1.30%  (67570) MELA /
Chryssis George C 0.98%  (51000) MELA /
Wagner Gerald D Acting Chief Operating Officer 0.90%  (46962) MELA /
Cleary Martin D 0.78%  (40443) MELA /
Swintek Kathryn B 0.64%  (33513) MELA /
Via LuAnn 0.55%  (28513) CBK / MELA /
Steinhart Richard I Chief Financial Officer 0.48%  (25000) ATOS / MELA / TGTX /
STONE DAVID K 0.45%  (23514) MELA /
Egger Anne M 0.31%  (16350) MELA /
BRAGINSKY SIDNEY 0.29%  (15000) MELA /
ODONNELL JEFFREY F 0.26%  (13513) ESMC / MELA /
Cook Robert W. Chief Financial Officer 0.19%  (10000) CRMD / IMNP / MELA /
Goddard John Geoffrey 0.19%  (10000) MELA /
MEADS MINDY C 0.10%  (5070) MELA / NILE / WTSL /
Kabelev Nikolai V.P. of R&D 0.09%  (4761) MELA /